Patents Assigned to NeuroDiagnostics LLC
  • Patent number: 12405268
    Abstract: This invention provides methods for diagnosing Alzheimer's disease in a symptomatic human subject, and for determining whether a human subject is predisposed to becoming afflicted with Alzheimer's disease. These methods employ the steps of (a) culturing a subject's lymphocytes with a suitable basement membrane matrix to permit the lymphocytes to aggregate; (b) measuring the resulting lymphocyte aggregation; and (c) based on such measurement, either diagnosing Alzheimer's disease or determining a predisposition to it, as appropriate.
    Type: Grant
    Filed: July 26, 2022
    Date of Patent: September 2, 2025
    Assignee: NeuroDiagnostics LLC
    Inventors: Florin Valentin Chirila, Daniel L. Alkon
  • Publication number: 20230111650
    Abstract: This invention provides methods for diagnosing Alzheimer's disease in a symptomatic human subject, and for determining whether a human subject is predisposed to becoming afflicted with Alzheimer's disease. These methods involve the steps of (a) culturing lymphocytes from the subject under suitable conditions; (b) measuring the amount of PKC? in the cultured lymphocytes; and (c) comparing the measurement of step (b) with a suitable control.
    Type: Application
    Filed: December 7, 2022
    Publication date: April 13, 2023
    Applicant: NeuroDiagnostics LLC
    Inventors: Florin Valentin Chirila, Daniel L. Alkon
  • Publication number: 20220357315
    Abstract: This invention provides methods for diagnosing Alzheimer's disease in a symptomatic human subject, and for determining whether a human subject is predisposed to becoming afflicted with Alzheimer's disease. These methods employ the steps of (a) culturing a subject's lymphocytes with a suitable basement membrane matrix to permit the lymphocytes to aggregate; (b) measuring the resulting lymphocyte aggregation; and (c) based on such measurement, either diagnosing Alzheimer's disease or determining a predisposition to it, as appropriate.
    Type: Application
    Filed: July 26, 2022
    Publication date: November 10, 2022
    Applicant: NeuroDiagnostics LLC
    Inventors: Florin Valentin Chirila, Daniel L. Alkon
  • Patent number: 11415574
    Abstract: This invention provides methods for diagnosing Alzheimer's disease in a symptomatic human subject, and for determining whether a human subject is predisposed to becoming afflicted with Alzheimer's disease. These methods employ the steps of (a) culturing a subject's lymphocytes with a suitable basement membrane matrix to permit the lymphocytes to aggregate; (b) measuring the resulting lymphocyte aggregation; and (c) based on such measurement, either diagnosing Alzheimer's disease or determining a predisposition to it, as appropriate.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: August 16, 2022
    Assignee: NeuroDiagnostics LLC
    Inventors: Florin Valentin Chirila, Daniel L. Alkon
  • Publication number: 20220128577
    Abstract: This invention provides methods for diagnosing Alzheimer's disease in a symptomatic human subject. These methods comprise measuring the growth rate, size and/or protein amount of a subject's skin fibroblasts and/or lymphocytes, and determining whether these values differ in certain ways from those of corresponding non-Alzheimer's disease dementia cells. This invention also provides methods for determining whether an asymptomatic human subject is at risk from becoming afflicted with Alzheimer's disease.
    Type: Application
    Filed: February 26, 2020
    Publication date: April 28, 2022
    Applicant: NeuroDiagnostics LLC
    Inventors: Florin Valentin Chirila, Daniel L. Alkon
  • Publication number: 20190323083
    Abstract: This invention provides a method for determining whether a human subject is afflicted with AD or non-ADD when the subject is suspected of being afflicted with AD or non-ADD, comprising the steps of (a) synchronizing a population of suitable cells derived from the subject; and (b) in the resulting synchronized cell population, measuring the expression level of a gene known to be differentially expressed between corresponding synchronized cells derived from AD patients and those derived from non-ADD patients, whereby (i) the subject is afflicted with AD if the expression level measured in step (b) is consistent with that gene's expression level in corresponding synchronized cells derived from AD patients, and (ii) the subject is afflicted with non-ADD if the expression level measured in step (b) is consistent with that gene's expression level in corresponding synchronized cells derived from non-ADD patients. This invention also provides diagnostic methods based on NDS patient gene expression levels.
    Type: Application
    Filed: June 7, 2019
    Publication date: October 24, 2019
    Applicant: NEURODIAGNOSTICS LLC
    Inventors: Florin Valentin Chirila, Daniel L. Alkon
  • Publication number: 20180284103
    Abstract: This invention provides methods for diagnosing Alzheimer's disease in a symptomatic human subject, and for determining whether a human subject is predisposed to becoming afflicted with Alzheimer's disease. These methods employ the steps of (a) culturing a subject's lymphocytes with a suitable basement membrane matrix to permit the lymphocytes to aggregate; (b) measuring the resulting lymphocyte aggregation; and (c) based on such measurement, either diagnosing Alzheimer's disease or determining a predisposition to it, as appropriate.
    Type: Application
    Filed: March 29, 2018
    Publication date: October 4, 2018
    Applicant: NeuroDiagnostics LLC
    Inventors: Florin Valentin Chirila, Daniel L. Alkon
  • Publication number: 20180282784
    Abstract: This invention provides methods for diagnosing Alzheimer's disease in a symptomatic human subject, and for determining whether a human subject is predisposed to becoming afflicted with Alzheimer's disease. These methods involve the steps of (a) culturing lymphocytes from the subject under suitable conditions; (b) measuring the amount of PKC? in the cultured lymphocytes; and (c) comparing the measurement of step (b) with a suitable control.
    Type: Application
    Filed: March 29, 2018
    Publication date: October 4, 2018
    Applicant: NeuroDiagnostics LLC
    Inventors: Florin Valentin Chirila, Daniel L. Alkon